Article
Ataluren in cystic fibrosis: development, clinical studies and where are we now?
22 Jul 2017
Abstract excerpt
INTRODUCTION: Cystic fibrosis (CF) is one of the most common genetically-acquired life-limiting conditions worldwide. The underlying defect is dysfunction of the cystic fibrosis transmembrane-conductance regulator (CFTR) which leads to progressive lung disease and other multi-system effects. Around 10% of people with CF have a class I nonsense mutation that leads to production of shortened CFTR due to a premature...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
